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INTRODUCTION
Recently, it has been reported that RUNX3, a RUNX
family gene, is related to the carcinogeneses of various solid
human tumors. The RUNX (Runt-related transcription fac-
tor) gene family is also referred to as the acute myeloid leu-
kemia (AML), core-binding factor- (CBF ), or polyoma en-
hancer-binding protein-2 (PEBP2 ) family (1) and encodes
the -subunit  of  PEBP2/CBF (2). Moreover, the heterodi-
meric RUNX-CBF complex is believed to be associated
with cellular differentiation and proliferation (3, 4). Three
RUNX family genes, i.e., RUNX1 (AML1/CBFA2/PEBP-
2aB), RUNX2 (AML3/CBFA1/PEBP2aA), and RUNX3
(AML2/CBFA3/PEBP2aC) have been detected in mammals
(1). RUNX1 is believed essential in hematopoiesis (5) and is
located in chromosome 21q22.3 (6). Moreover, it is target-
ed for translocation (7) or mutation (8) in acute and chronic
leukemia or myelodysplastic syndrome. RUNX2 on chro-
mosome 6q21 (9) is regarded as indispensable for the devel-
opment of the musculoskeletal system (10) and has been
related with cleidocranial dysplasia (11). On the other hand,
RUNX3 gene is located on chromosome 1p36, 30.31 kb-
sized (1), composed of 5 exons (12), and is believed to be asso-
ciated with solid tumor carcinogenesis.
Although many have reported an association between
RUNX3 inactivation and solid tumor carcinogenesis, e.g.,
gastric cancer (13-17), colorectal cancer (18, 19), lung can-
cer (20-22), esophageal cancer (23), hepatocellular carcino-
ma (24-26), pancreatic cancer (27), and yolk sac tumor (28),
others found no such correlations (29).
Several mechanisms including promoter region hyperme-
thylation, loss of heterozygosity, hemizygous deletion, and
mutation are believed to be correlated with the downregula-
tion of the RUNX3 gene, and have been causally linked with
the carcinogeneses in a wide range of human solid tumors.
Little information is available on the relationship between
the RUNX3 gene and breast cancer, other than the hyper-
methylation that was observed in 25% of 25 breast cancer
tissues by Kim et al. (15). In order to reveal the relationship
between the RUNX3 gene and breast cancer and its mode
of action, we performed reverse transcriptase-polymerase chain
reaction (RT-PCR), methylation-specific PCR (MSP) and
bicolor fluorescent in situ hybridization (FISH) on 40 breast
tissues and 13 cell lines.
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Downregulation of the RUNX3 Gene by Promoter Hypermethylation
and Hemizygous Deletion in Breast Cancer
The RUNX3 gene is regarded as a tumor suppressor gene in many human solid
tumors, and its inactivation is believed to be related with solid tumor carcinogene-
sis. As little information is available about the role of the RUNX3 gene in breast can-
cer, we investigated the relationship between the RUNX3 gene and breast cancer.
We performed reverse transcriptase-polymerases chain reaction (RT-PCR), methy-
lation specific PCR, and bicolor fluorescent in situ hybridization analysis in an effort
to reveal related mechanisms. Forty breast tissue samples and 13 cell lines were
used in this study. Eighty-five percent of breast cancer tissues showed downregu-
lated RUNX3 gene expression, whereas it was downregulated in only 25% of nor-
mal breast tissues by RT-PCR assay. Sixty-seven percent of breast cancer cell
lines showed downregulated RUNX3 expression, but the RUNX3 gene was not
expressed in two normal breast cell lines. Hypermethylation was observed in 53%
of breast cancer tissues and 57% of breast cancer cell lines. Hemizygous deletion
was observed in 43% of breast cancer cell lines. Hypermethylation and/or hemizy-
gous deletion was observed in 5 of 7 breast cancer cell lines, and the four of these
five examined showed no RUNX3 gene expression. We suggest that various me-
chanisms, including methylation and hemizygous deletion, could contribute to
RUNX3 gene inactivation.
Key Words : RUNX3; Hypermethylation; Hemizygous Deletion; Breast Cancer
Received : 8 January 2007
Accepted : 22 March 2007Expression of RUNX3 Gene in Breast Caner S25
MATERIALS AND METHODS
Tissue collection
Forty breast tissue samples (20 normal breast tissues and
20 breast cancer tissues) were collected for this study. These
tissue samples were obtained during resective surgery, imme-
diately frozen in liquid nitrogen, and stored at -80℃ until
required for DNA and RNA extraction. Breast cancer tissue
samples were macrodissected through the centers of carcino-
matous regions and then normal breast tissue samples, well
separate from cancer bearing regions, were macrodissected.
The pathologic classification of all 20 breast cancer tissues was
of infiltrating ductal carcinoma. This study was performed
with given patient consent at Seoul National University Hos-
pital. 
Cell lines
Thirteen cell lines were used in this study. Eight cell lines
(Hs 578T, MCF-7, MDA-MB-231, SCC-1395, SK-BR-3,
ZR-75-1, SNU1, and SNU5) were obtained from the Kore-
an Cell Line Bank (Seoul), and the other five (MCF10A,
MCF-7 TH, MDA-MB-468, MDA-MB-436, and T-47D)
from the American Type Culture Collection (ATCC). Two
cell lines, SCC-1395 and MCF 10A, were used as non-can-
cer controls. These two cell lines originated from normal
breast tissue and breast tissue showing fibrocystic change,
respectively. Another two cell lines, SNU1 and SNU5, origi-
nated from gastric carcinoma. Because the SNU1 cell line is
known to have only methylated DNA products by MSP, it
was used as a positive control for MSP. Similarly, because
the SNU5 cell line has only unmethylated DNA products, it
was used as a negative control. The remaining 9 cell lines
originated from breast cancer (ZR-75-1, MCF 7, SK-BR-3,
Hs 578T, MDA-MB-231, T-47D, MDA-MB-436, MDA-
MB-468, and MCF-7 TH).
Cell culture
Seven cell lines, namely, SCC-1395, ZR-75-1, MCF7, T-
47D, MCF-7 TH, SNU1, and SNU5, were cultured in Ros-
well Park Memorial Institute (RPMI) 1640 enriched with
1% penicillin/streptomycin and 10% fetal bovine serum
(FBS). MDA-MB-231, MDA-MB-436, and Hs 578T were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
containing 1% penicillin/streptomycin and 10% FBS. SK-
BR-3 and MDA-MB-468 were cultured in DMEM/F-12
(Nutrient Mixture F-12) containing 1% penicillin/strepto-
mycin and 10% FBS, and MCF 10A was cultured in DM-
EM/F-12 containing 1% penicillin/streptomycin, 5% horse
serum (all of the above were purchased from GibcoBRL,
NY, U.S.A.), 10  g/mL insulin, 10 ng/mL epithelial growth
factor, 0.5 ng/mL hydrocortisone, and 0.1  g/mL cholera
toxin (Sigma-Aldrich, St. Louis, MO). Cell culture plates were
maintained in humidified incubators at 37℃ in a 5% CO2
atmosphere.
RT-PCR
Total RNA was extracted from breast cancer tissues and
cell lines using TRIzol
� reagent (Invitrogen, CA, U.S.A.),
and complementary DNA was synthesized from total RNA
with deoxyribonucleotide triphosphate (dNTP) mix, RNase
I (Ribonuclease Inhibitor), dithiothreitol (DTT), diethylpy-
rocarbonate (DEPC), RNA, 5 X first-stand buffer, Moloney
Murine Leukemia Virus (M-MLV) reverse transcriptase (In-
vitrogen) and random primer. Complementary DNA was
amplified using a RUNX3 gene specific primer with com-
plementary DNA template, dNTP, Taq polymerase, distilled
water (DW), and 10X buffer. Initial denaturation was per-
formed at 94℃ for 5 min, and this was followed by 35 am-
plification cycles ( 30 sec at 95℃, 55℃, and 72℃). Final elo-
ngation was performed at 72℃ for 10 min, and  -actin was
used as a control.
The primers used to amplify RUNX3 and  -actin were as
follows: sense for RUNX3, 5′ -GAG TTT CAC CCT GAC
CAT CAC TGT G-3′ ; antisense for RUNX3, 5′ -GCC CAT
CAC TGG TCT TGA AGG TTG T-3′ (869 base pairs); sense
for -actin,  5′ -CAC TGT GTT GGC GTA CAG GT-3′ ; an-
tisense for  -actin, 5′ -TCA TCA CCA TTG GCA ATG AG-
3′ (155 base pairs). Electrophoresis was followed by visualiza-
tion under ultraviolet light after loading the amplified PCR
products on 2% agarose gel containing ethidium bromide.
We classified the level of RUNX3 expression into 3 types
such as weak, moderate, and strong expression in compari-
son with the expression level of  -actin. Strong expression
means that the level of RUNX3 expression is almost same
with that of  -actin. When the expression of RUNX3 is
visible but very faint, we classified it as weak expression. If
the expression of RUNX3 is intermediate between strong
and weak, then we regard it as moderate expression.
MSP
One Day MSP kits (In2Gen Co., Seoul) were used to deter-
mine the promoter methylation status of the RUNX3 gene
in genomic DNA extracted from breast cancer tissues and
cell lines. Initial denaturation was performed at 95℃ for 15
min followed by 40 amplification cycles of; 95℃ (20 sec),
60℃ (40 sec), and 72℃ (60 sec). Final elongation was per-
formed at 72℃for 3 min.
The following primers were used as previously described
by Li et al. (13): sense for methylation, 5′ -TTA CGA GGG
GCG GTC GTA CGC GGG-3′ ; antisense for methylation,
5′ -AAA ACG ACC GAC GCG AAC GCC TCC-3′ (220
base pairs); sense for non-methylation, 5′ -TTA TGA GGG
GTG GTT GTA TGT GGG-3′ ; antisense for non-methy-S26 K.-T. Hwang, W. Han, J.-Y. Bae, et al.
lation, 5′ -AAA ACA ACC AAC ACA AAC ACC TCC-3′
(212 base pairs). After electrophoresis on 2% agarose gel con-
taining ethidium bromide, the amplified PCR products were
visualized under ultraviolet light.
Bicolor FISH analysis
Cells (1×106/mL) fixed with Carnoy’s solution (methanol:
acetic acid, 3:1) were mixed with 0.1% Nonidet P-40 (NP-
40)/2× standard saline citrate (SSC) solution for 30 min to
increase cell membrane permeabilities and dehydrated for 3
min in a 70%, 85%, 100% ethanol series. All of the follow-
ing procedures were performed in the dark. A probe mixture
prepared from RUNX3 gene-specific probe tagged with Cy3,
and a 1q21.1 specific probe tagged with FITC (control) was
mixed with human Cot-1 DNA, salmon sperm DNA, and
hybridization buffer. Denaturation and hybridization (DA-
KO, Hamburg, Germany) were performed after dropping a
probe mixture on a slide containing cells followed by DAPI
solution for background staining. The RUNX3 gene-specific
probe was tagged with Cy3 release orange and the 1q21.1
specific probe was tagged with FITC release green. 
After performing the above, 100 cells from each cell lines
were randomly observed. If the green staining exceeded the
orange staining in a single cell, then the O/G (O and G mean
orange and green staining, respectively) ratio was defined to
be less than 1. If O/G ratios were less than 1 in more than
20% of observed cells, then hemizygous deletion of the RU-
NX3 gene was presumed in the affected cell line.
RESULTS
RUNX3 gene expression by RT-PCR in breast cancer
tissues and cell lines
RUNX3 gene expression was not observed in five (num-
bers 3, 8, 14, 17, and 19) of the 20 normal breast tissue sam-
ples, but only three samples (numbers 4, 5, and 9) of 20 breast
cancer tissues showed RUNX3 gene expression (Fig. 1, Table
1). RUNX3 gene expression was observed in six cell lines,
namely, MDA-MB-436, SCC-1395, T-47D, ZR-75-1, MCF
10A, and SNU-5 (Table 2), and whereas SNU-5 showed
strong expression, three cell lines, i.e., MDA-MB-436, T-
47D, and ZR-75-1, showed weak expression. Moderate ex-
pression was observed in SCC-1395 and MCF 10A (Fig. 2).
The RT-PCR product sizes for the RUNX3 and -actin  genes
were 869 and 155 base pairs, respectively. 
Analysis of RUNX3 methylation by MSP in breast cancer
tissues and cell lines
MSP results were available in 19 of the 20 breast cancer
tissues. Sample number 19 was excluded because of the insuf-
ficient amount of specimen for repeated experiments. Methy-
lated DNA products were observed in 10 breast cancer tis-
sues (samples 2-4, 6, 8, 10, 11, 13, 14, and 15) and unme-
thylated DNA products in 18 breast cancer tissues (except-
ing only sample 13). Nine breast cancer tissues (samples 2-
A
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Fig. 1. RT-PCR analysis of RUNX3 gene expression in normal and breast cancer tissues. RUNX3 downregulation was observed in 5 of 20
normal breast tissues (A), but in 17 of 20 breast cancer tissues (B).
RT-PCR, reverse transcriptase-polymerase chain reaction; U, unmethy-
lation; M, methylation; -, negative; ?, unknown.
Breast cancer 
tissue
RT-PCR Unmethylation Methylation
1( -)U-
2( -)UM
3( -)UM
4( + ) U M
5( + ) U -
6( -)UM
7( -)U-
8( -)UM
9( + ) U -
10 (-)UM
11 (-)UM
12 (-)U-
13 (-) - M
14 (-)UM
15 (-)UM
16 (-)U-
17 (-)U-
18 (-)U-
19 (-)??
20 (-)U-
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4, 6, 8, 10, 11, 14, and 15) showed both methylated and
unmethylated DNA products (Fig. 3). Ten out of thirteen
cell lines showed the results of MSP, and results were inade-
quate for three cell lines, i.e., SCC-1395, Hs 578T, and T-
47D. Methylated DNA products were observed in 6 cell
lines, i.e., MCF7, SNU-1, MDA-MB-231, SK-BR-3, MCF-
7 TH, and MCF 10A, and unmethylated DNA products in
5 cell lines, i.e., MDA-MB-436, MDA-MB-468, SK-BR-3,
RT-PCR, reverse transcriptase-polymerase chain reaction; FISH, fluo-
rescent in situ hybridization; U, unmethylation; M, methylation; D, hem-
izygous deletion; -, negative; ?, unknown.
Cell lines
Hemizygous
deletion 
by FISH
RT-PCR Unmethylation
Methy-
lation
SCC-1395 (+) ? ? ?
MCF 10A (+) - M -
ZR-75-1 (+) U --
MCF7 (-) - MD
SK-BR-3 (-)UM D
Hs 578T (-)???
MDA-MB-231 (-) - M -
T-47D (+) ? ? ?
MDA-MB-436 (+) U - D
MDA-MB-468 (-)U--
MCF-7 TH (-) - M?
SNU-1 (-) - MD
SNU-5 (+) U - D
Table 2. Summary of breast cell line results
RUNX3
MCF-TH
MCF7
MDA-MD-231
MDA-MD-468
MDA-MD-436
SK-BR-3
SCC 1395
Hs578T
T47D
ZR-75-1
-actin
Fig. 2. RT-PCR analysis of RUNX3 gene expression in 13 breast
cell lines. RUNX3 gene expression was observed in six cell lines
(MDA-MB-436, SCC-1395, T47D, ZR-75-1, MCF10A, and SNU-5).
SNU-5 showed strong expression, whereas SNU-1 showed none.
SCC-1395 and MCF10A showed moderate expression, and MDA-
MB-436, T47D, and ZR-75-1 showed weak expression.
RUNX3
MCF10A
SNU-1
SNU-5
-actin
Fig. 3. Methylation analysis of the RUNX3 gene in breast cancer tissues. The results of MSP were available for 19 samples (except sam-
ple 19; data for sample 14 is not shown in this figure.) Methylated DNAs were found in 10 samples (samples 2, 3, 4, 6, 8, 10, 11, 13, 14,
and 15), and all except one (sample number 13) contained unmethylated DNAs. Nine breast cancer tissues (samples 2, 3, 4, 6, 8, 10, 11,
14, and 15) contained both methylated and unmethylated DNA. U and M denote unmethylation and methylation, respectively. N denotes
normal human genomic DNA, which was used as an unmethylated PCR control, and DW is an abbreviation for distilled water, which was
used as a negative PCR control.
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ZR-75-1, and SNU-5. Methylated and unmethylated DNA
products were only observed in SK-BR-3 (Fig. 4). The prod-
uct sizes of the methylation and unmethylation MSP primers
were 220 and 212 base pairs, respectively.
Results of bicolor FISH analysis in cell lines
Bicolor FISH results were obtained in 9 cell lines, except
SCC-1395, Hs 578T, T-47D, and MCF-7 TH (Table 3). These
results were classified into 5 different patterns, i.e., normal,
O/G<1, O/G>1, hypoploid, and hyperploid. If one, two, or
more than 2 pairs of orange and green colors were observed
in a single cell, then the cell was classified as hypoploid, nor-
mal, and hyperploid, respectively. If the amount of green was
greater or smaller than the amount of orange, then the cell
of interest was classified as O/G<1 or O/G>1, respectively.
Because more than 20% of cells showed O/G<1 for the MB
436, MCF7, SK-BR-3, SNU-1, and SNU-5 cell lines, hem-
Fig. 4. Methylation analysis of the RUNX3 gene in cells. MSP results were available for 10 cell lines (except SCC-1395, Hs 578T, and T-
47D). Methylated DNA was found in 6 cell lines (MCF7, SNU-1, MDA-MB-231, SK-BR-3, MCF-7 TH, and MCF 10A), and unmethylated
DNA in 5 (MDA-MB-436, MDA-MB-468, SK-BR-3, ZR-75-1, and SNU-5). U and M denote unmethylation and methylation, respectively. N
denotes normal human genomic DNA, which was used as an unmethylated PCR control, and DW is an abbreviation for distilled water,
which was used as a negative PCR control.
SNU-1 
MDA-MB-231
MDA-MB-436
MDA-MB-468
N
DW
MCF7
UM UMUMU U MM U M
1,000 bp
850 bp
650 bp
500 bp
400 bp
300 bp
200 bp
100 bp
SK-BR-3
ZR-75-1
MCF-7 TH
UM UM UM
1,000 bp
850 bp
650 bp
500 bp
400 bp
300 bp
200 bp
100 bp
SNU-5
MCF 10A
DW
UM UM UM
1,000 bp
850 bp
650 bp
500 bp
400 bp
300 bp
200 bp
100 bp
1,000 bp
850 bp
650 bp
500 bp
400 bp
300 bp
200 bp
100 bp
UM
*Cell exhibited 2 pairs of orange and green colors; 
� The ratio of orange
(representing the RUNX3 gene) to green (control) in the observed cell
was less than 1; 
� The ratio of orange to green was more than 1; 
�Cell
exhibited 2 pairs of orange and green colors; 
‖Cell exhibited more than
2 pairs of orange and green colors.
FISH, fluorescent in situ hybridization.
Cell lines Hyperp-
loidy (%)
‖
Hypop-
loidy (%)
�
O/G >1 
(%)
�
O/G <1
(%)
�
Normal
(%)*
MCF 10A 100 0 0 0 0
ZR-75-1 95 2 0 0 3
MDA MB 436 16.4 80 0 1.8 1.8
MCF7 0 100 0 0 0
SK-BR-3 0 95.8 0 0 4.2
MDA MB 231 36.7 1.7 0 0 61.7
MDA MB 468 0 4 44 0 52
SNU-1 17.4 34.8 4.3 0 43.5
SNU-5 0 93.3 0 0 6.7
Table 3. Results of bicolor FISH analysisExpression of RUNX3 Gene in Breast Caner S29
izygous deletion of the RUNX3 gene was deemed to be pre-
sent in these cell lines. Less than 20% of cells showed O/G
<1 in ZR-75-1, MDA MB 231, and MDA MB 468, and
no cell had an O/G<1 in MCF 10A. All MCF 10A cells and
95% of ZR-75-1 cells showed a normal pattern, whereas all
MCF7 cells had an O/G of <1 (Fig. 5). Only 2 cell lines, i.e.,
MDA MB 468 and SNU-1, had an O/G of >1, and only
MDA MB 436 showed a hypoploid pattern. Seven cell lines,
except MCF 10A and MCF7, showed various degrees of
hyperploidy.
DISCUSSION
Recently it was reported that RUNX3 gene expression is
downregulated in various solid tumors in vivo. While Li et
al found that RUNX3 gene expression was downregulated
in 60% of gastric cancer tissues and in 47% of gastric can-
cer cell lines (13), Sakakura et al. found that RUNX3 gene
expression was downregulated in 78% of gastric cancer tis-
sues and in 69% of gastric cancer cell lines (14). Regarding
colorectal cancer cell lines, Ku et al. reported that 50% show-
ed decreased RUNX3 gene expression (18), and Goel et al.
found that RUNX3 gene expression was downregulated in
65% of colorectal cancer cell lines (19). Other studies have
reported various degrees of RUNX3 downregulation in lung
cancer, esophageal cancer, hepatocellular carcinoma, pancre-
atic cancer, and others. However, little data is available on
the relationship between RUNX3 gene expression and breast
cancer.
In the present study, 85% of breast cancer tissues (17 of 20
samples) showed RUNX3 gene downregulation, whereas it
was downregulated in only 25% of normal breast tissues (5
of 20) by RT-PCR. Regarding the cell lines, 67% of breast
cancer cell lines (6 of 9) showed RUNX3 downregulation,
although in two normal breast cell lines (SCC-1395 and
MCF 10A) RUNX3 gene expression was not detected. SNU-
5 is known to possess only unmethylated DNA and showed
strong RUNX3 expression, and SNU-1 is known to possess
only methylated DNA and showed no RUNX3 expression.
Moreover, while SCC-1395 and MCF 10A showed moder-
ate expression, 3 of 9 breast cancer cell lines (MDA-MB-436,
T-47D, and ZR-75-1) showed weak expression. These results
imply that RUNX3 expression is downregulated in breast
cancer and that this downregulation is related its carcinoge-
nesis, as described for other cancers above.
Several genetic and epigenetic events may explain the me-
chanism underlying RUNX3 downregulation, such as, pro-
moter region hypermethylation, loss of heterozygosity, mic-
rosatellite instability, hemizygous deletion, and mutation.
Li et al found loss of heterozygosity in 30% of gastric cancer
tissues and 20% of gastric cancer cell lines, and that hyper-
methylation is related to RUNX3 gene expression (13). They
also have found one mutation in the RUNX3 gene among
119 gastric cancer tissue samples. Ku et al. have reported
hypermethylation in 18.4% of colorectal cancer tissues and
in 37.5% of colorectal cancer cell lines. Yanada et al. also
found hypermethylation in 53% of lung cancer cell lines and
loss of heterozygosity in 53% of lung cancer cell lines (22).
Especially, promoter region hypermethylation was of very
wide range from 2.5-73% in various tumor samples. Little
information is available on breast cancer, but Kim et al. re-
ported their observation of hypermethylation in 25% of 25
breast cancer tissues (15). In the present study, hypermethy-
lation was observed in 53% (10 of 19) of breast cancer tis-
sues and in 57% (4 of 7) breast cancer cell lines, and hem-
izygous deletion was observ- ed in 43% (3 of 7) breast can-
cer cell lines. The results of our study on breast tissue and
cell lines are summarized in Table 1, 2.
In breast cancer tissues, methylated DNA was found in
10 of 19 breast cancer tissues (53%), and RUNX3 gene ex-
pression was not observed in these samples except for one
sample (sample 4) by RT-PCR (Table 1). Unmethylated DNA
was observed in 18 breast cancer tissues (95%) except for
Fig. 5. Bicolor FISH analysis. Orange is produced by RUNX3 probe and green by control probe on 1q21.1. Ninety-five percent of ZR-75-1
cells showed a normal pattern (A), and O/G ratios of patterns were observed in all MCF7 cells (B).
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sample 13, which showed only methylated DNA. Nine sam-
ples (47%) showed both methylated and unmethylated DNA.
Although nine breast cancer tissues (47%) had only unme-
thylated DNA, the expression of RUNX3 gene was observ-
ed in only 2 of these samples. In addition, sample 4 showed
RUNX3 expression despite having methylated DNA. These
results suggest that a mechanism other than methylation of
RUNX3 promoter influences RUNX3 gene expression. With
regard to cell lines, MSP results were available for 10 cell
lines and bicolor FISH results for 9 cell lines (Table 2). Methy-
lated DNA was observed in 6 cell lines (MCF 10A, MCF7,
SK-BR-3, MDA-MB-231, MCF-7 TH, and SNU-1), where-
as four cell lines (ZR-75-1, MDA-MB-436, MDA-MB-468,
and SNU-5) contained only unmethylated DNA. Only SK-
BR-3 showed both methylated and unmethylated DNA.
Hemizygous deletion was observed in 5 cell lines (MCF7,
SK-BR-3, MDA-MB-436, SNU-1, and SNU-5), and hyper-
methylation and/or hemizygous deletion in five cell lines
(MCF7, SK-BR-3, MDA-MB-231, MDA-MB-436, and
MCF-7 TH) of 7 breast cancer cell lines with available results,
and 4 of these 5 cell lines did not show RUNX3 expression.
Despite the hemizygous deletion in MDA-MB-436 (which
contained only unmethylated DNA), RUNX3 expression
was observed. In the case of MDA-MB-468, which contain-
ed only unmethylated DNA without hemizygous deletion,
RUNX3 expression was not apparent. These results imply
that a mechanism other than hypermethylation or hemizy-
gous deletion participates in RUNX3 gene expression.
In conclusion, RUNX3 gene expression was found to be
downregulated in breast cancer. In addition, it is evident
that several mechanisms of RUNX3 gene inactivation, includ-
ing methylation and hemizygous deletion, contribute to the
development of breast cancer.
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